Compare Stocks: ME, INCR, TLPH, and HRTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$0.34	$0.41	$0.30 ▼ $1.58	$65.29M	1.61	3.24 million shs	1.87 million shs
INCR InterCure	$5.42	$4.98	$3.40 ▼ $8.45	$59.30M	1.42	44,040 shs	6,343 shs
ME 23andMe	$0.61	$0.50	$0.53 ▼ $9.57	$16.27M	1.19	1.57 million shs	N/A
TLPH Talphera	$1.20	$1.27	$0.50 ▼ $1.57	$62.29M	0.69	288,987 shs	58,863 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	0.00%	+5.30%	-29.93%	-24.18%	-73.75%
INCR InterCure	0.00%	-6.23%	+10.61%	+9.49%	-31.39%
ME 23andMe	0.00%	0.00%	0.00%	0.00%	+21.75%
TLPH Talphera	0.00%	0.00%	-16.08%	+41.71%	+118.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$0.34	$0.41	$0.30 ▼ $1.58	$65.29M	1.61	3.24 million shs	1.87 million shs
INCR InterCure	$5.42	$4.98	$3.40 ▼ $8.45	$59.30M	1.42	44,040 shs	6,343 shs
ME 23andMe	$0.61	$0.50	$0.53 ▼ $9.57	$16.27M	1.19	1.57 million shs	N/A
TLPH Talphera	$1.20	$1.27	$0.50 ▼ $1.57	$62.29M	0.69	288,987 shs	58,863 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	0.00%	+5.30%	-29.93%	-24.18%	-73.75%
INCR InterCure	0.00%	-6.23%	+10.61%	+9.49%	-31.39%
ME 23andMe	0.00%	0.00%	0.00%	0.00%	+21.75%
TLPH Talphera	0.00%	0.00%	-16.08%	+41.71%	+118.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRTX Heron Therapeutics	2.00	Hold	$2.00	481.56% Upside
INCR InterCure	1.00	Sell	N/A	N/A
ME 23andMe	0.00	N/A	N/A	N/A
TLPH Talphera	2.25	Hold	$3.00	150.00% Upside

Current Analyst Ratings Breakdown

Latest ME, INCR, TLPH, and HRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00
8/11/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/3/2026	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	HRTX Heron Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	TLPH Talphera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	INCR InterCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	INCR InterCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/8/2026	TLPH Talphera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRTX Heron Therapeutics	$154.90M	0.42	N/A	N/A	$0.07 per share	4.91
INCR InterCure	$78.47M	0.76	N/A	N/A	$10.53 per share	0.51
ME 23andMe	$208.78M	0.08	$0.65 per share	0.93	$2.34 per share	0.26
TLPH Talphera	$30K	2,076.40	N/A	N/A	$0.37 per share	3.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRTX Heron Therapeutics	-$20.19M	-$0.19	N/A	N/A	N/A	-22.52%	-293.02%	-10.00%	11/3/2026 (Estimated)
INCR InterCure	-$10.37M	$0.15	36.13	N/A	N/A	N/A	N/A	N/A	N/A
ME 23andMe	-$666.70M	-$15.45	N/A	N/A	N/A	-183.39%	-170.07%	-62.13%	N/A
TLPH Talphera	-$14.29M	-$0.27	N/A	N/A	N/A	N/A	-87.28%	-51.36%	11/11/2026 (Estimated)

Latest ME, INCR, TLPH, and HRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	TLPH Talphera	-$0.0625	-$0.06	+$0.0025	-$0.06	N/A	N/A
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
ME 23andMe	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRTX Heron Therapeutics	24.35	2.49	1.51
INCR InterCure	0.20	1.48	0.97
ME 23andMe	N/A	1.05	0.91
TLPH Talphera	N/A	4.29	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRTX Heron Therapeutics	80.01%
INCR InterCure	8.34%
ME 23andMe	36.10%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
HRTX Heron Therapeutics	6.10%
INCR InterCure	N/A
ME 23andMe	26.32%
TLPH Talphera	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRTX Heron Therapeutics	300	189.85 million	178.27 million	Optionable
INCR InterCure	350	10.94 million	N/A	Optionable
ME 23andMe	770	26.83 million	19.77 million	Not Optionable
TLPH Talphera	19	51.91 million	50.09 million	Optionable

ME, INCR, TLPH, and HRTX Headlines

Recent News About These Companies

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026 | prnewswire.com

Talphera Earnings Call Highlights Nafamostat Momentum

August 23, 2026 | tipranks.com

Talphera (TLPH) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

HC Wainwright Issues Positive Estimate for Talphera Earnings

August 17, 2026 | marketbeat.com

Talphera, Inc. (TLPH) Q2 FY2026 earnings call transcript

August 14, 2026 | finance.yahoo.com

HC Wainwright Has Negative View of Talphera FY2029 Earnings

August 14, 2026 | marketbeat.com

Talphera, Inc. (TLPH) Stock Major Holders - Yahoo Finance

August 13, 2026 | finance.yahoo.com

Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as ...

August 13, 2026 | uk.finance.yahoo.com

Talphera signals ~$200,000 annual U.S. CRRT procedures in 2027 market sizing as NEPHRO CRRT reaches 75% enrollment

August 13, 2026 | seekingalpha.com

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | aol.comA

Talphera Q2 Earnings Call Highlights

August 12, 2026 | marketbeat.com

Talphera (NASDAQ:TLPH) Issues Earnings Results, Meets Estimates

August 12, 2026 | marketbeat.com

Talphera Q2 2026 earnings preview

August 11, 2026 | msn.com

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

August 5, 2026 | prnewswire.com

Talphera, Inc. Common Stock

July 15, 2026 | fxempire.comF

Talphera (TLPH) CEO Angotti buys $85k in shares

May 21, 2026 | investing.com

Talphera Earnings Call Highlights NEPHRO Trial Momentum

May 19, 2026 | tipranks.com

Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...

May 15, 2026 | finance.yahoo.com

Talphera Earnings Call Highlights Trial Momentum, Risks

May 14, 2026 | tipranks.com

Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ME, INCR, TLPH, and HRTX Company Descriptions

Heron Therapeutics NASDAQ:HRTX

$0.34 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

InterCure NASDAQ:INCR

$5.42 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

23andMe NASDAQ:ME

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Talphera NASDAQ:TLPH

$1.20 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ME, INCR, TLPH, and HRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ME, INCR, TLPH, and HRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ME, INCR, TLPH, and HRTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ME, INCR, TLPH, and HRTX Company Descriptions

Heron Therapeutics NASDAQ:HRTX

InterCure NASDAQ:INCR

23andMe NASDAQ:ME

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ME, INCR, TLPH, and HRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ME, INCR, TLPH, and HRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ME, INCR, TLPH, and HRTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ME, INCR, TLPH, and HRTX Company Descriptions

Heron Therapeutics NASDAQ:HRTX

InterCure NASDAQ:INCR

23andMe NASDAQ:ME

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools